scholarly journals Treatment of Age-Related Hearing Loss in Dogs with the Vibrant Soundbridge Middle Ear Implant: Short-Term Results in 3 Dogs

2010 ◽  
Vol 24 (3) ◽  
pp. 557-564 ◽  
Author(s):  
G. Ter Haar ◽  
J.J. Mulder ◽  
A.J. Venker-van Haagen ◽  
F.J. Van Sluijs ◽  
A.F. Snik ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Middle Ear ◽  
Vibrant Soundbridge ◽  
Short Term ◽  
Middle Ear Implant ◽  
Age Related ◽  
Age Related Hearing Loss

scholarly journals Outcome of Vibrant Soundbridge Middle Ear Implant in Cantonese-Speaking Mixed Hearing Loss Adults

2012 ◽  
Vol 5 (Suppl 1) ◽  
pp. S82 ◽  
Author(s):  
Joannie Ka Yin Yu ◽  
Willis Sung Shan Tsang ◽  
Terence Ka Cheong Wong ◽  
Michael Chi Fai Tong
Keyword(s):  
Hearing Loss ◽  
Middle Ear ◽  
Vibrant Soundbridge ◽  
Middle Ear Implant ◽  
Mixed Hearing Loss

Risk Factors of Age-related Hearing Loss, Adults over 65 Years in Korea: Including the Effect of the War Participation

2016 ◽  
Vol 17 (2) ◽  
pp. 68-73
Author(s):  
Dong-Wook Kim ◽  
Tae-Young Lee ◽  
Da-Hye Choi ◽  
Taek-Yeong Kim ◽  
Hyun-Chul Moon
Keyword(s):  
Risk Factors ◽  
Hearing Loss ◽  
Age Related ◽  
Age Related Hearing Loss

scholarly journals Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice

2021 ◽  
Vol 22 (6) ◽  
pp. 2853
Author(s):  
Judit Szepesy ◽  
Viktória Humli ◽  
János Farkas ◽  
Ildikó Miklya ◽  
Júlia Tímár ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Hearing Aids ◽  
Dose Range ◽  
Auditory Brainstem ◽  
High Frequency Hearing Loss ◽  
Age Related ◽  
Hearing Function ◽  
Brainstem Response ◽  
Aging Societies ◽  
Age Related Hearing Loss

Age-related hearing loss (ARHL), a sensorineural hearing loss of multifactorial origin, increases its prevalence in aging societies. Besides hearing aids and cochlear implants, there is no FDA approved efficient pharmacotherapy to either cure or prevent ARHL. We hypothesized that selegiline, an antiparkinsonian drug, could be a promising candidate for the treatment due to its complex neuroprotective, antioxidant, antiapoptotic, and dopaminergic neurotransmission enhancing effects. We monitored by repeated Auditory Brainstem Response (ABR) measurements the effect of chronic per os selegiline administration on the hearing function in BALB/c and DBA/2J mice, which strains exhibit moderate and rapid progressive high frequency hearing loss, respectively. The treatments were started at 1 month of age and lasted until almost a year and 5 months of age, respectively. In BALB/c mice, 4 mg/kg selegiline significantly mitigated the progression of ARHL at higher frequencies. Used in a wide dose range (0.15–45 mg/kg), selegiline had no effect in DBA/2J mice. Our results suggest that selegiline can partially preserve the hearing in certain forms of ARHL by alleviating its development. It might also be otoprotective in other mammals or humans.

Sign in / Sign up

Export Citation Format

Share Document